Dr. Ansbert Gadicke is co-founder and Managing Director of MPM and its venture capital activities, Managing Partner of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities managed by MPM. He is the driving force at MPM behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Oncology (NASDAQ: CGEM), iTeos Therapeutics (NASDAQ: ITOS) and AlloVir (NASDAQ: ALVR).
Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office. Ansbert is active in guiding MPM portfolio companies and serves as Chairman of the Board at NextPoint Therapeutics, Orna, and TCR2 Therapeutics (NASDAQ: TCRR) and as a Board Director at Cullinan Oncology (NASDAQ: CGEM), ElevateBio and Allovir (NASDAQ: ALVR). He is also a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.
Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt and has held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University.